.

Make Better Decisions

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Accenture
Novartis
Moodys
Farmers Insurance
Julphar
Healthtrust
Citi
Johnson and Johnson
US Army

Generated: November 19, 2017

DrugPatentWatch Database Preview

Ferring Company Profile

« Back to Dashboard

What is the competitive landscape for FERRING, and when can generic versions of FERRING drugs launch?

FERRING has twenty-four approved drugs.

There are sixteen US patents protecting FERRING drugs.

There are one hundred and fifty-four patent family members on FERRING drugs in thirty-eight countries and twelve supplementary protection certificates in eleven countries.

Summary for Ferring

International Patents:154
US Patents:16
Tradenames:24
Ingredients:14
NDAs:24
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring Pharms Inc
DDAVP
desmopressin acetate
INJECTABLE;INJECTION018938-001Mar 30, 1984APRXYesYes► Subscribe► Subscribe► Subscribe
Ferring
ENDOMETRIN
progesterone
INSERT;VAGINAL022057-001Jun 21, 2007RXYesYes► Subscribe► SubscribeY ► Subscribe
Ferring Pharms Inc
DDAVP
desmopressin acetate
INJECTABLE;INJECTION018938-002Apr 25, 1995DISCNNoNo► Subscribe► Subscribe► Subscribe
Ferring
CHORIONIC GONADOTROPIN
gonadotropin, chorionic
INJECTABLE;INJECTION017016-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ferring
FIRMAGON
degarelix acetate
POWDER;SUBCUTANEOUS022201-002Dec 24, 2008RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ferring Pharms As
LYSTEDA
tranexamic acid
TABLET;ORAL022430-001Nov 13, 2009ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Ferring Pharms As
LYSTEDA
tranexamic acid
TABLET;ORAL022430-001Nov 13, 2009ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Ferring Pharms As
LYSTEDA
tranexamic acid
TABLET;ORAL022430-001Nov 13, 2009ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Ferring
A.P.L.
gonadotropin, chorionic
INJECTABLE;INJECTION017055-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Ferring
BIO-TROPIN
somatropin recombinant
INJECTABLE;INJECTION019774-001May 25, 1995DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Ferring

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ferring Pharms Inc
DDAVP
desmopressin acetate
SOLUTION;NASAL017922-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Ferring Pharms Inc
DDAVP
desmopressin acetate
TABLET;ORAL019955-001Sep 6, 1995► Subscribe► Subscribe
Ferring Pharms Inc
DDAVP
desmopressin acetate
TABLET;ORAL019955-002Sep 6, 1995► Subscribe► Subscribe
Ferring Pharms Inc
DDAVP
desmopressin acetate
INJECTABLE;INJECTION018938-001Mar 30, 1984► Subscribe► Subscribe
Ferring
ACTHREL
corticorelin ovine triflutate
INJECTABLE;INJECTION020162-001May 23, 1996► Subscribe► Subscribe
Ferring Pharms Inc
DDAVP
desmopressin acetate
TABLET;ORAL019955-001Sep 6, 1995► Subscribe► Subscribe
Ferring Pharms Inc
CERVIDIL
dinoprostone
INSERT, EXTENDED RELEASE;VAGINAL020411-001Mar 30, 1995► Subscribe► Subscribe
Ferring Pharms Inc
DDAVP (NEEDS NO REFRIGERATION)
desmopressin acetate
SPRAY, METERED;NASAL017922-003Aug 7, 1996► Subscribe► Subscribe
Ferring Pharms Inc
DDAVP
desmopressin acetate
SPRAY, METERED;NASAL017922-002Feb 6, 1989► Subscribe► Subscribe
Ferring Pharms Inc
DDAVP
desmopressin acetate
TABLET;ORAL019955-001Sep 6, 1995► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for FERRING drugs

Drugname Dosage Strength Tradename Submissiondate
sodium picosulfate, magnesium oxide and anhydrous citric acid
Oral Solution10 mg, 3.5 g, and 12 g
PREPOPIK
5/21/2014
tranexamic acid
Tablets650 mg
LYSTEDA
5/24/2011

Non-Orange Book Patents for Ferring

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,214,798 GnRH antagonists being modified in positions 5 and 6► Subscribe
8,841,081Method of treating metastatic stage prostate cancer► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ferring Drugs

Country Document Number Estimated Expiration
Eurasian Patent Organization020543► Subscribe
Slovakia139699► Subscribe
Hong Kong1145011► Subscribe
Eurasian Patent Organization200901074► Subscribe
European Patent Office2505204► Subscribe
Japan2008508276► Subscribe
Slovenia2505204► Subscribe
Russian Federation2504394► Subscribe
Portugal2650012► Subscribe
World Intellectual Property Organization (WIPO)0028970► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Ferring Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009000033Germany► SubscribePRODUCT NAME: DEGARELIX, GGF. IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON, WIE DEM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001-002 20090217
2009005Lithuania► SubscribePRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
2009 00022Denmark► Subscribe
0395Netherlands► Subscribe300395, 20180413, EXPIRES: 20230412
1003774/01Switzerland► SubscribePRODUCT NAME: DEGARELIX; REGISTRATION NUMBER/DATE: SWISSMEDIC 59455 12.02.2010
C/GB09/028United Kingdom► SubscribePRODUCT NAME: DEGARELIX OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT SUCH AS THE ACETATE; REGISTERED: UK EU/1/08/504/001 20090217; UK EU/1/08/504/002 20090217
C0028France► SubscribePRODUCT NAME: DEGARELIX, SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/504/001 DU 20090217; REGISTRATION NO/DATE AT EEC: EU/1/08/504/001 DU 20090217
2009005,C1003774Lithuania► SubscribePRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
585Luxembourg► SubscribePRODUCT NAME: DEGARELIX, EVENTUELLEMENT UN SEL PHARMACEUTIQUEMENT ACCEPTABE, TEL QUE L'ACETATE (FIRMAGON); REG. DATE: 20090217
2Finland► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Chinese Patent Office
Daiichi Sankyo
McKesson
Teva
US Army
Cantor Fitzgerald
Accenture
UBS
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot